Research programme: hepatitis B therapeutics - Riboscience
Latest Information Update: 24 May 2022
At a glance
- Originator Riboscience
- Class Antivirals; Nucleosides; Small molecules
- Mechanism of Action Hepatitis B virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Hepatitis B
Most Recent Events
- 22 Apr 2022 Early research in Hepatitis B in USA (Parenteral) (Riboscience pipeline, April 2022)